Collective Molecular Activities of the Plant: Symphytum Tuberosum
Example Image
PLANiTS DNA barcode
Taxonomic Information
Plant ID: NPO9866
Plant Latin Name: Symphytum Tuberosum
Taxonomy Genus: Symphytum
Taxonomy Family: Boraginaceae
Plant External Links:
NCBI TaxonomyDB:
256504
Plant-of-the-World-Online:
n.a.
Used in Medicines
Country/Region:
China; SpainTraditional Medicine System:
TCMGeographical Distribution
China; Spain
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Compounds Summary
Overview of Ingredients
47 All known Ingredients in Total
Unique ingredients have been isolated from this plant.Plant-Ingredients Associations were manually curated from publications or collected from other databases.
11 Ingredients with Acceptable Bioavailablity
Unique ingredients exhibit acceptable human oral bioavailablity, according to the criteria of SwissADME [PMID: 28256516] and HobPre [PMID: 34991690]. The criteria details:SwissADME: six descriptors are used by SwissADME to evaluate the oral bioavailability of a natural product:
☑ LIPO(Lipophility): -0.7 < XLOGP3 < +5.0
☑ SIZE: 150g/mol < MW < 500g/mol
☑ POLAR(Polarity): 20Ų < TPSA < 130Ų
☑ INSOLU(Insolubility): -6 < Log S (ESOL) < 0
☑ INSATU(Insaturation): 0.25 < Fraction Csp3 < 1
☑ FLEX(Flexibility): 0 < Num. rotatable bonds < 9
If 6 descriptors of a natural plant satisfy the above rules, it will be labeled high HOB.
HobPre: A natural plant ingredient with HobPre score >0.5 is labeled high human oral availability (HOB)
16 Ingredients with experimental-derived Activity
Unique ingredients have activity data available.Ingredient Structrual Cards
Ingredient ID: NPC92898
Ingredient ID: NPC8990
Ingredient ID: NPC7780
Ingredient ID: NPC76859
Ingredient ID: NPC74150
Ingredient ID: NPC73738
Ingredient ID: NPC70361
Ingredient ID: NPC59326
Ingredient ID: NPC53475
Ingredient ID: NPC42234
Ingredient ID: NPC3450
Ingredient ID: NPC308191
Ingredient ID: NPC282285
Ingredient ID: NPC281452
Ingredient ID: NPC276652
Ingredient ID: NPC27154
Ingredient ID: NPC270364
Ingredient ID: NPC264653
Ingredient ID: NPC26229
Ingredient ID: NPC261341
Ingredient ID: NPC259168
Ingredient ID: NPC252593
Ingredient ID: NPC24873
Ingredient ID: NPC24580
Ingredient ID: NPC243595
Ingredient ID: NPC242861
Ingredient ID: NPC23322
Ingredient ID: NPC230301
Ingredient ID: NPC215626
Ingredient ID: NPC212755
Ingredient ID: NPC206438
Ingredient ID: NPC206264
Ingredient ID: NPC202964
Ingredient ID: NPC175214
Ingredient ID: NPC159362
Ingredient ID: NPC156358
Ingredient ID: NPC151859
Ingredient ID: NPC145218
Ingredient ID: NPC144015
Ingredient ID: NPC143569
Ingredient ID: NPC137949
Ingredient ID: NPC122504
Ingredient ID: NPC11977
Ingredient ID: NPC118799
Ingredient ID: NPC118405
Ingredient ID: NPC11666
Ingredient ID: NPC105222
Classification of Human Proteins Collectively Targeted by the Plant
*The classification criteria of Drug Transporter (DTP), CYP450 are referred to DrugMap. Other molecular targets in CMAUP are classified as therapeutic targets.
.
Detailed Information of Target Proteins
| Target Type | Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|---|
| Therapeutic Target | Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Therapeutic Target | Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Therapeutic Target | Oxidoreductase | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Therapeutic Target | Phosphodiesterase | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Therapeutic Target | Protein Kinase | PRKCD | Protein kinase C delta | Q05655 | CHEMBL2996 |
Clinical Trials Summary
Overview
Clinical trials associated with plant from natural product (NP) & plant level:
| Clinical trials type | Number of clinical trials | |
|---|---|---|
 NP level | 148 | |
Clinical trial details
| NCT ID | Title | Condition | Form in clinical use | Associated by plant or compound |
|---|---|---|---|---|
| NCT05087914 | Novel Non-opioid Post-surgical Pain Treatment in Females | pain | Levodopa (NPC161593) | NP level |
| NCT04513340 | WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT04082715 | Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity | Back pain | Levodopa (NPC161593) | NP level |
| NCT00335153 | Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01883505 | A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612 | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00485069 | REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT03243552 | Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD | autism spectrum disorder | Levodopa (NPC161593) | NP level |
| NCT02169414 | Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01519284 | Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00660673 | Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00099268 | Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00634556 | Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol) | Tourette syndrome | Levodopa (NPC161593) | NP level |
| NCT01479127 | Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00829439 | Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome | Angelman syndrome | Levodopa (NPC161593) | NP level |
| NCT01725802 | A Phase I/IIa Study of Safety, Tolerability and Plasma Concentration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02170376 | The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00601978 | Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT04990284 | eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00143026 | Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00279825 | Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01281475 | A Trial of Levodopa in Angelman Syndrome | Angelman syndrome | Levodopa (NPC161593) | NP level |
| NCT03103399 | Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02312232 | Pharmacokinetic Study in Healthy Males | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00660387 | Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01568047 | Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01636037 | Antipsychotic Augmentation With L-Dopa | schizophrenia | Levodopa (NPC161593) | NP level |
| NCT05471609 | Sustained Release Oral Formulation for Treatment of Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00914134 | Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01351168 | Use of Zolpidem in Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT03000569 | A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT04000919 | Effects of 5HTP and LDOPA on CNS Excitability After SCI | Spinal cord injury | Levodopa (NPC161593) | NP level |
| NCT00625547 | A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS | restless legs syndrome | Levodopa (NPC161593) | NP level |
| NCT01484990 | A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00004733 | Timing of Levodopa Treatment in Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00253084 | Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01770145 | Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01568034 | A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067 | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT03022318 | Carbidopa-levodopa in Neovascular AMD | age-related macular degeneration | Levodopa (NPC161593) | NP level |
| NCT02641054 | Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02837640 | Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa | retinitis pigmentosa | Levodopa (NPC161593) | NP level |
| NCT00505843 | A Study of MK0657 in Parkinson's Disease Patients (0657-006) | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT04952194 | Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01387711 | PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology | actinic keratosis | Ingenol (NPC261341) | NP level |
| NCT02080819 | Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse | cocaine dependence | Levodopa (NPC161593) | NP level |
| NCT02554734 | Pharmacokinetic Study in Healthy Volunteers | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02601586 | Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02633839 | A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults | nicotine dependence | Levodopa (NPC161593) | NP level |
| NCT01484184 | Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury | Spinal cord injury | Levodopa (NPC161593) | NP level |
| NCT00108667 | Talampanel to Treat Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02812394 | A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00360568 | Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01429077 | Augmenting Language Therapy for Aphasia: Levodopa | Aphasia;stroke | Levodopa (NPC161593) | NP level |
| NCT00141518 | Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT05128175 | Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01171313 | A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01515410 | Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT04558112 | Improving Therapeutic Learning for PTSD | post-traumatic stress disorder | Levodopa (NPC161593) | NP level |
| NCT01736176 | A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00144209 | Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome | restless legs syndrome | Levodopa (NPC161593) | NP level |
| NCT02242487 | Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00845000 | Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550) | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT04006210 | Efficacy, Safety and Tolerability Study of ND0612 vs. Oral IR-LD/CD in Subjects With PD Experiencing Motor Fluctuations | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02769793 | Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT03887884 | Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT04591535 | PK Study of WD-1603 in Healthy Subjects | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01960842 | A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT03140956 | Pharmacokinetic of Levodopa Study in Healthy Males | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT03496870 | A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa. | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01227655 | Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01663935 | Vision Response to Dopamine Replacement | oculocutaneous albinism | Levodopa (NPC161593) | NP level |
| NCT00006077 | Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00076674 | Levetiracetam Treatment of L-dopa Induced Dyskinesias | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT03119636 | Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT03576638 | Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01176435 | Trial of L-DOPA as a Treatment to Improve Vision in Albinism | albinism | Levodopa (NPC161593) | NP level |
| NCT00558337 | Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00406588 | SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00642356 | Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00218075 | Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence | cocaine dependence | Levodopa (NPC161593) | NP level |
| NCT02873351 | A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration | age-related macular degeneration | Levodopa (NPC161593) | NP level |
| NCT02486432 | A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00590122 | Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00040209 | JP-1730 to Treat Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT05132660 | Treating Early Stage Diabetic Retinopathy | diabetic retinopathy | Levodopa (NPC161593) | NP level |
| NCT02352363 | Randomized Safety Study of CVT-301 Compared to an Observational Control Group | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00009048 | EMD 128130 for the Treatment of Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01070628 | Levodopa Concentration Profile With Stalevo 75/125 mg | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00918177 | An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01468012 | Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence | cocaine dependence | Levodopa (NPC161593) | NP level |
| NCT01617135 | Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT03929068 | Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis | amyotrophic lateral sclerosis | Levodopa (NPC161593) | NP level |
| NCT02847442 | Efficacy and Safety of Opicapone in Clinical Practice | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00745277 | High and Low Dose Carbidopa Treatment of Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02807675 | A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder) | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00789672 | Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia | amblyopia | Levodopa (NPC161593) | NP level |
| NCT02073773 | Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients Recovering From Motor Stroke | stroke | Levodopa (NPC161593) | NP level |
| NCT03205956 | Measuring Parkinson's Disease Progression | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01777555 | Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02096601 | A Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00888186 | Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00357994 | Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02240030 | Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00914602 | An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01568073 | Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02271503 | A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01393457 | Cognitive Remediation for Cocaine Dependence | cocaine dependence | Levodopa (NPC161593) | NP level |
| NCT00399477 | A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00391898 | Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02778594 | Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02347059 | L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02549092 | A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02116790 | Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects | pain | Levodopa (NPC161593) | NP level |
| NCT02741947 | Levodopa Benserazide Generic Formulation Versus the Originator | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT03007888 | A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT04380142 | Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT03023059 | Dose Ranging Study of Carbidopa-levodopa | age-related macular degeneration | Levodopa (NPC161593) | NP level |
| NCT00174239 | Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease. | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00272688 | Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00134966 | A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00218023 | Medications for Stopping Cocaine Dependence and Preventing Relapse | cocaine dependence | Levodopa (NPC161593) | NP level |
| NCT02633007 | A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma | asthma | Levodopa (NPC161593) | NP level |
| NCT02480803 | INfusion VErsus STimulation in Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT02764125 | Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC) | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00006337 | KW-6002 to Treat Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00713583 | Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence | cocaine dependence | Levodopa (NPC161593) | NP level |
| NCT01646255 | Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00086294 | ACP-103 to Treat Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT05036473 | A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01026428 | A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT03451500 | Carbidopa-Levodopa in Dry AMD With Geographic Atrophy | age-related macular degeneration | Levodopa (NPC161593) | NP level |
| NCT01190813 | Levodopa for the Treatment of Residual Amblyopia | amblyopia | Levodopa (NPC161593) | NP level |
| NCT00089622 | Lisuride Patch to Treat Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT03735901 | Enhancement of Stroke Rehabilitation With Levodopa | stroke | Levodopa (NPC161593) | NP level |
| NCT02577523 | A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT04052776 | Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES | Spinal cord injury | Levodopa (NPC161593) | NP level |
| NCT02799381 | A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER) | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00219284 | Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00125567 | Stalevo in Early Wearing-Off Patients | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT05285683 | The Role of Brain Dopamine in Chronic Pain | Chronic pain | Levodopa (NPC161593) | NP level |
| NCT05369533 | Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke | stroke | Levodopa (NPC161593) | NP level |
| NCT01533116 | Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00013624 | Riluzole to Treat Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00906828 | Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT01504178 | Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT04244058 | Changes in Glutamatergic Neurotransmission of Severe TBI Patients | brain injury | Levodopa (NPC161593) | NP level |
| NCT00153972 | Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease | Parkinson disease | Levodopa (NPC161593) | NP level |
| NCT00223691 | Treatment of Orthostatic Hypotension in Autonomic Failure | orthostatic hypotension | Levodopa (NPC161593) | NP level |
| NCT01283594 | Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off | Parkinson disease | Levodopa (NPC161593) | NP level |
❱❱❱ Associated Human Diseases and Detailed Association Evidence
How do we define the Plant-Targeted Human Disease Association?
Associated human diseases of an individual plant are summurized based on FOUR types of association evidence, these include:
❶ Association by Therapeutic Target: Bioactive protein targets of the plant were defined in "Molecular Targets" section, target-disease associations collected from TTD database were subsequently used to build the associations between the plant and its targeted human diseases.
❷ Association by Disease Gene Reversion: Plant and a specific disease will be associated when >= 1 plant target gene overlaped with disease's DEGs.
❸ Association by Clinical Trials of Plant: Plant and a specific disease will be associated when >= 1 clinical trial (the plant is the intervetion) can be matched in ClinicalTrials.gov database.
❹ Association by Clinical Trials of Plant Ingredients: Plant and a specific disease will be associated when >= 1 clinical trial (the plant ingredient is the intervetion) can be matched in ClinicalTrials.gov database.
Associated Disease of the Plant |
Association Type & Detailed Evidence |
|---|---|
Cocaine use disorderDisease Category: 06.Mental, behavioural or neurodevelopmental disordersDisease ICD-11 Code: 6C45 |
NCT00218023,NCT01393457,NCT00218075,NCT01468012,NCT00713583,NCT02080819
|
Ischaemic/haemorrhagic strokeDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8B20 |
F2
NCT01429077,NCT03735901,NCT02073773,NCT05369533 |
Diffuse large B-cell lymphomasDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A81 |
HSD17B10,ALDH1A1,CA9,CA12,TDP1
|
Macular degenerationDisease Category: 09.Diseases of the visual systemDisease ICD-11 Code: 9B75 |
NCT03022318,NCT02873351,NCT03023059,NCT03451500
|
Serous cystadenoma,borderline malignancy of ovaryDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C73.4 |
PRKCD,CA9,CA12,TDP1
|
Hepatocellular carcinoma of liverDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C12.02 |
CA9,CA12,CA9,CA12
|
Injury of spinal cord, level unspecifiedDisease Category: 22.Injury, poisoning or certain other consequences of external causesDisease ICD-11 Code: ND51.2 |
NCT01484184,NCT04052776,NCT04000919
|
Carcinosarcoma of uterusDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C76.43 |
CA9,TDP1,HSD17B10
|
Other specified malignant neoplasms of kidney, except renal pelvisDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C90.Y |
CA9,CA9,F2
|
Squamous cell carcinoma of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.2 |
CA9,CA12,F2
|
Adenocarcinoma of pancreasDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C10.0 |
CA9,F2,PRKCD
|
Mesothelioma of pleuraDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C26.0 |
CA9,CA12,TDP1
|
Adenocarcinoma of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.0 |
CA9,CA12,F2
|
Solid tumour/cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00-2F9Z |
CA9,CA12
|
Myocardial infarctionDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BA41-BA43 |
PRKCD,F2
|
Breast cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C60-2C6Y |
CA9,CA12
|
AsthmaDisease Category: 12.Diseases of the respiratory systemDisease ICD-11 Code: CA23 |
F2
NCT02633007 |
Pain, unspecifiedDisease Category: 21.Symptoms, signs or clinical findings, not elsewhere classifiedDisease ICD-11 Code: MG3Z |
NCT02116790,NCT05087914
|
Impairment of binocular functionsDisease Category: 09.Diseases of the visual systemDisease ICD-11 Code: 9D46 |
NCT01190813,NCT00789672
|
Angelman syndromeDisease Category: 20.Developmental anomaliesDisease ICD-11 Code: LD90.0 |
NCT00829439,NCT01281475
|
Restless legs syndromeDisease Category: 07.Sleep-wake disordersDisease ICD-11 Code: 7A80 |
NCT00144209,NCT00625547
|
Malignant neoplasms of biliary tract, distal bile ductDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C15 |
CA9,PRKCD
|
Malignant neoplasm metastasis in lymph nodes of head, face or neckDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D60.0 |
CA9,F2
|
Other specified malignant neoplasms ofcolonDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B90.Y |
CA9,F2
|
Other specified malignant neoplasms of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.Y |
CA9,CA12
|
Malignant neoplasms of corpus uteri, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C76.Z |
CA9,F2
|
Malignant neoplasms of thymusDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C27 |
CA9,HSD17B10
|
Invasive carcinoma of breastDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C61 |
CA9,CA12
|
Glioblastoma of brainDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00.00 |
CA9,CA12
|
Renal cell carcinoma, chromophobe typeDisease Category: X.Extension CodesDisease ICD-11 Code: XH6153 |
CA12,PRKCD
|
Germ cell tumour of testisDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C80.2 |
CA12,F2
|
Malignant neoplasms of adrenal glandDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D11 |
CA9,CA12
|
ParkinsonismDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8A00 |
NCT00918177,NCT00099268,NCT02312232,NCT01568047,NCT01568073,NCT03007888,NCT01519284,NCT00253084,NCT00406588,NCT01883505,NCT02601586,NCT01484990,NCT02480803,NCT00660387,NCT00914134,NCT02271503,NCT01171313,NCT00006077,NCT00279825,NCT03103399,NCT00601978,NCT00399477,NCT03496870,NCT00086294,NCT02096601,NCT00642356,NCT00888186,NCT00219284,NCT00360568,NCT02847442,NCT04952194,NCT02242487,NCT00013624,NCT03000569,NCT01515410,NCT02486432,NCT01725802,NCT00153972,NCT02799381,NCT00906828,NCT02554734,NCT02352363,NCT00391898,NCT00845000,NCT01777555,NCT00089622,NCT01568034,NCT00272688,NCT02641054,NCT03140956,NCT01646255,NCT01504178,NCT03205956,NCT05128175,NCT01026428,NCT02769793,NCT00590122,NCT00141518,NCT00485069,NCT04513340,NCT01070628,NCT01736176,NCT00134966,NCT00335153,NCT01770145,NCT04591535,NCT04990284,NCT00009048,NCT01533116,NCT01617135,NCT02764125,NCT02549092,NCT05471609,NCT01960842,NCT00040209,NCT04006210,NCT00125567,NCT01283594,NCT04380142,NCT05036473,NCT02778594,NCT00076674,NCT02812394,NCT00174239,NCT02741947,NCT01227655,NCT00108667,NCT02240030,NCT02347059,NCT03119636,NCT00006337,NCT00004733,NCT00660673,NCT00914602,NCT02170376,NCT02577523,NCT01351168,NCT00558337,NCT01479127,NCT02169414,NCT03576638,NCT02807675,NCT00357994,NCT00745277,NCT00505843,NCT03887884,NCT00143026
|
Cardiovascular diseaseDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BA00-BE2Z |
F2
|
Coronary thrombosisDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BA43 |
F2
|
Seborrhoeic dermatitisDisease Category: 14.Diseases of the skinDisease ICD-11 Code: EA81 |
CA12
|
Bleeding disorderDisease Category: 16.Diseases of the genitourinary systemDisease ICD-11 Code: GA20-GA21 |
F2
|
ThrombocytopeniaDisease Category: 03.Diseases of the blood or blood-forming organsDisease ICD-11 Code: 3B64 |
F2
|
Bacterial infectionDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1A00-1C4Z |
CA12
|
Cerebral ischaemic strokeDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8B11 |
F2
|
Coagulation defectDisease Category: 03.Diseases of the blood or blood-forming organsDisease ICD-11 Code: 3B10 |
F2
|
Mature T-cell lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A90 |
CA9
|
Nutritional deficiencyDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5B50-5B71 |
F2
|
Renal cell carcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C90 |
CA9
|
Angina pectorisDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BA40 |
F2
|
Type 2 diabetes mellitusDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A11 |
F2
|
Substance abuseDisease Category: 06.Mental, behavioural or neurodevelopmental disordersDisease ICD-11 Code: 6C40 |
ALDH1A1
|
Multiple sclerosisDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8A40 |
F2
|
ThrombosisDisease Category: 13.Diseases of the digestive systemDisease ICD-11 Code: DB61-GB90 |
F2
|
AphasiaDisease Category: 21.Symptoms, signs or clinical findings, not elsewhere classifiedDisease ICD-11 Code: MA80.0 |
NCT01429077
|
Neuropathy, ataxia, and retinitis pigmentosaDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8C73.1 |
NCT02837640
|
Actinic keratosisDisease Category: X.Extension CodesDisease ICD-11 Code: XH36H6 |
NCT01387711
|
Chronic painDisease Category: 21.Symptoms, signs or clinical findings, not elsewhere classifiedDisease ICD-11 Code: MG30 |
NCT05285683
|
Orthostatic hypotensionDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BA21 |
NCT00223691
|
Amyotrophic lateral sclerosisDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8B60.0 |
NCT03929068
|
Tourette syndromeDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8A05.00 |
NCT00634556
|
Intracranial injury, unspecifiedDisease Category: 22.Injury, poisoning or certain other consequences of external causesDisease ICD-11 Code: NA07.Z |
NCT04244058
|
OculocutaneousalbinismDisease Category: 14.Diseases of the skinDisease ICD-11 Code: EC23.20 |
NCT01663935
|
Post-traumatic stress disorderDisease Category: 06.Mental, behavioural or neurodevelopmental disordersDisease ICD-11 Code: 6B40 |
NCT04558112
|
SchizophreniaDisease Category: 06.Mental, behavioural or neurodevelopmental disordersDisease ICD-11 Code: 6A20 |
NCT01636037
|
Albinism or other specified genetically-determined hypomelanotic disordersDisease Category: 14.Diseases of the skinDisease ICD-11 Code: EC23.2 |
NCT01176435
|
Nicotine use disorderDisease Category: 06.Mental, behavioural or neurodevelopmental disordersDisease ICD-11 Code: 6C4A |
NCT02633839
|
Spinal painDisease Category: 21.Symptoms, signs or clinical findings, not elsewhere classifiedDisease ICD-11 Code: ME84 |
NCT04082715
|
RetinopathyDisease Category: 09.Diseases of the visual systemDisease ICD-11 Code: 9B71 |
NCT05132660
|
Autism spectrum disorderDisease Category: 06.Mental, behavioural or neurodevelopmental disordersDisease ICD-11 Code: 6A02 |
NCT03243552
|
Osteoarthritis, unspecifiedDisease Category: 15.Diseases of the musculoskeletal system or connective tissueDisease ICD-11 Code: FA0Z |
CA12
|
HepatoblastomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C12.01 |
CA12
|
Adenocarcinoma of stomachDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B72.0 |
F2
|
Tetralogy of FallotDisease Category: 20.Developmental anomaliesDisease ICD-11 Code: LA88.2 |
F2
|
Melanoma of skinDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C30 |
ALDH1A1
|
Urothelial carcinoma of bladderDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C94.2 |
CA9
|
Chronic rhinosinusitisDisease Category: 12.Diseases of the respiratory systemDisease ICD-11 Code: CA0A |
CA9
|
Malignant neoplasms of thyroid gland, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D10.Z |
CA12
|
Parkinson diseaseDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8A00.0 |
ALDH1A1
|
❱❱❱ Network Visualization of Plant-Targeted Human Disease Associations
Plant-Targeted Human Disease Network
>> Targets derived from weak experimental activities
